provenge

Several patients have inquired about Medicare coverage for the recently approved drug, sipuleucel-T(Provenge) for the treatment of metastatic castrate-resistant prostate cancer. The Centers for Medicare and Medicaid is performing a "national coverage analysis to determine whether autologous cellular immunotherapy is reasonable and necessary under certain sections of the Social Security Act". More information will be forthcoming as it becomes available